公开(公告)号：US20210188936A1

公开(公告)日：2021-06-24

申请号：US16606279

申请日：2018-04-20

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun CHOI ,  In Hwan LIM ,  Jun Young PARK ,  Jin Hyoung LEE ,  Ki Hong KIM ,  Hae Yong JO ,  Jun Hwan KIM ,  Moo Young SONG ,  Jong Gyun KIM

IPC: C07K14/605 ,  C07K14/50 ,  C12P21/02

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20230212249A1

公开(公告)日：2023-07-06

申请号：US18068506

申请日：2022-12-19

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun CHOI ,  In Hwan LIM ,  Jun Young PARK ,  Jin Hyoung LEE ,  Ki Hong KIM ,  Hae Yong JO ,  Jun Hwan KIM ,  Moo Young SONG ,  Jong Gyun KIM

IPC: C07K14/605 ,  C12P21/02 ,  C07K14/50 ,  C07K19/00 ,  C07K16/46 ,  C12N5/00 ,  C12N15/00

CPC classification number: C07K14/605 ,  C12P21/02 ,  C07K14/50 ,  C07K19/00 ,  C07K16/46 ,  C12N5/00 ,  C07K2319/30 ,  C12N15/00

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20210221869A1

公开(公告)日：2021-07-22

申请号：US17256296

申请日：2019-07-24

Applicant: YUHAN CORPORATION ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Moo Young SONG ,  Taejin YOON ,  Jung-Sun LEE ,  Byung Hyun CHOI ,  In Hwan LIM ,  Man Sil PARK ,  Jin-Hyoung LEE ,  Hyoung Sig SEO ,  Hyeon Woo KANG ,  Sung Ho KIM ,  Eun Jig LEE ,  Jin Sook YOON ,  Cheol Ryong KU

IPC: C07K14/72

Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.